Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
JBIO Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: May 21, 2026
Report Source: 2026 1st Quarter Report
Jade Biosciences Inc. Stock Analysis JBIO
United States Health Care Small Cap Report: Jade Biosciences, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. The company is headquartered in Waltham, Massachusetts and currently employs 55 full-time employees. The company went IPO on 2021-06-30. The Company’s lead asset, JADE-001, is an investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of Immunoglobulin A (IgA) nephropathy (IgAN), an autoimmune condition in which the kidney is damaged by pathogenic IgA containing immune complexes, leading to proteinuria and kidney function decline, and potentially progressing to end-stage kidney disease requiring dialysis or transplantation. Designed to block the APRIL protein, JADE-001 targets an underlying cause of IgAN, offering the potential to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function over the long term. The Company’s pipeline also includes two undisclosed antibody discovery programs: JADE-002 and JADE-003, which are in preclinical development.
Read More Jade Biosciences Inc (JBIO) Chart
Key Statistics of Jade Biosciences Inc (JBIO)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$19.24Volume
1.41MP/E Ratio (TTM)
-52 Week Range
Market Cap
1.16BAvg. Volume
1.53MDividend Yield
-Financial Metrics & Statements of Jade Biosciences Inc (JBIO)
FAQ's for Jade Biosciences Inc (JBIO)
- According to Musaffa’s Shariah screening methodology, Jade Biosciences Inc (JBIO) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Jade Biosciences Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Jade Biosciences Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Jade Biosciences Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Jade Biosciences Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Jade Biosciences Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.